Defendant

Alembic Pharmaceuticals Limited

2 cases as defendant.

Cases
2
Active
0
2 closed
Filed
2021–2022
Top venue
D. Delaware
1 case

Company profile

Company overview. Alembic Pharmaceuticals Limited ("Alembic") is an Indian multinational pharmaceutical company headquartered at Alembic Road, Vadodara, Gujarat, India. Its corporate lineage dates to 1907, when Alembic Chemical Works Company Ltd. was founded; the current listed entity was incorporated in 2010. It is publicly traded on the National Stock Exchange (APLLTD) and BSE (533573), with market capitalization commonly reported around ₹13,000–16,000 crore (roughly US$1.5–2 billion) during 2026. FY2025 revenue was about ₹6,672 crore (approx. US$800 million). Third-party trackers put headcount at roughly 17,000–20,000; sources vary, so treat the exact figure as approximate.

Products / services. Alembic is a vertically integrated generics manufacturer, operating three segments: India branded formulations, international generics, and active pharmaceutical ingredients (APIs). It runs six formulation and three API plants, mostly in Gujarat (Panelav, Karakhadi, Jarod) plus Sikkim, with R&D in Vadodara, Hyderabad, and New Jersey. Therapeutic areas include dermatology, cardiology, oncology, ophthalmology, anti-infectives (notably macrolides), diabetes, gastroenterology, orthopedics, gynecology, and animal health. The U.S. arm, Alembic Pharmaceuticals, Inc. (Bridgewater, NJ), sits under Alembic Global Holding SA; in 2025 it acquired Utility Therapeutics Ltd., holder of the UTI drug Pivya (pivmecillinam).

Patent-litigation posture. Alembic is an operating company defending against pharma patent suits, not an assertion entity. In the tracked data it appears in one case, as defendant only (0 as plaintiff), consistent with Hatch-Waxman ANDA litigation rather than NPE activity. The single case sits in the U.S. District Court for the District of Delaware — the standard venue for ANDA disputes — not a plaintiff-friendly venue such as the Eastern District of Texas.

Notable case. Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited (D. Del., 1:22-cv-01277), filed September 28, 2022, concerned Alembic's ANDA No. 217678 for generic 15 mg binimetinib tablets (brand: Mektovi). Asserted patents included U.S. 9,314,464; 9,850,229; 10,005,761; 9,562,016; 9,598,376; and 9,980,944. Array is a Pfizer subsidiary. The parties settled and entered a settlement and license agreement; the case was dismissed by stipulation in June 2025.

Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited et al.

settled
Docket:
1:22-cv-01277-GBW
Filed:
2022-09-28
Terminated:
2025-06-10

Hatch-Waxman ANDA litigation brought by Array BioPharma against Alembic over generic binimetinib 15 mg tablets (ANDA No. 217678). The case was terminated by stipulated dismissal after a confidential settlement and license agreement, expressly not an adjudication on the merits, with no finding of infringement, invalidity, or unenforceability. A May 28, 2024 stipulated order addressed certain claims but did not become a final, appealable judgment.